Recovery from Loss, Guidance into Trash
Revenue jumped 25.3% and PAT swung from a ₹15.8 Cr loss to ₹7.8 Cr profit — but specialty polymers smashed guidance, working capital ate debt reduction, and margins are razor-thin. The post-result pop faded because the street saw through the accounting optics.
₹7.8 Cr
vs loss ₹15.8 Cr YoY; +149.7%
1.8%
vs OPM 9.0%; PAT recovery masks thin margins
₹29.3 Cr
−49% YoY (was ₹57.4 Cr); breaks FY27 guidance
₹34.5 Cr
8.3% margin; turnaround from ₹6.2 Cr loss YoY
The paradox: profit jumps 150%, but the quarter broke guidance
On the screen, Q2 FY-27 looks like a swing: PAT from a ₹15.8 Cr loss to ₹7.8 Cr profit, a 149.7% climb. But step back and the real story is narrower. Consolidated EBITDA margin is 10% (up 510 bps YoY), but the net margin collapse to 1.8% reveals a year-over-year base effect that's distorting optics. More importantly, this quarter formally broke the prior guidance on specialty polymers, veered wildly on working capital, and planted the question: is this recovery durable, or a rebound into a softer H2?
What holds up: films are real, specialty isn't
Polyester films EBIT turnaround to ₹34.5 Cr vs loss ₹6.2 Cr YoY
Consolidated OPM 9.0%, film segment EBIT at ₹34.5 Cr (Q2) / ₹73.6 Cr (H1) with 8.3% / 9% margins. Volume growth 13.9% YoY, revenue up 39.6% — pricing power evident.
Supported
Specialty Polymers declining at flat-to-single-digit rates in FY27
Q2 revenue ₹29.3 Cr (down 49% YoY from ₹57.4 Cr); H1 revenue ₹62 Cr (down 41% YoY from ₹105 Cr). Caused by technology/process change at largest customer; acknowledged as demand erosion, not pricing.
Contradicted — guidance implicitly missed by >40pp
VAS products growing ~25% YoY in polyester films; targeting 35% by Q4 FY27
VAS currently 26% of film volume; 25% YoY growth claimed but no prior-quarter baseline provided. Target 35% Q4, then 50–60% over 2–3 years is explicit.
Unverified for prior guidance; Q4 target repeated but not evidenced yet
Debt repayment on track: ₹53.5 Cr in H1 toward ₹100 Cr target
Gross debt rose from ₹729 Cr (Mar 26) to ₹748.8 Cr (Sept 26) due to WC buildup. H1 receivables +₹79 Cr, inventory +₹36 Cr; total WC increase ₹86.7 Cr. Net debt pressure despite repayment.
Overstated — absolute debt rose; repayment offset by WC buildup
rPET to exceed 100% capacity by exit quarter; installed 28,000 MT
Q2 rPET volume 1,437 MT; annualized ~5,700–6,000 MT ≈ 20% of 28,000 MT capacity. No utilization data provided; capacity-exceeded claim not substantiated.
Contradicted — no evidence; claim appears withdrawn without explanation
What changed on this call
Specialty Polymers FY27 guidance reset: flat-to-single-digit clearly missed (−41% H1); now guiding 25% CAGR from much lower FY27 base
Working capital headwind unveiled: ₹86.7 Cr H1 increase due to crude/freight inflation; not pre-called in prior guidance; limiting debt reduction agenda
Elite JV scope formalized: 45,000 MT polyester chips, ₹1,200–1,400 Cr capex, 40–45% EBITDA target, Nike anchor customer locked, leading sports brand LOI for 15,000 MT/year
Specialty films VAS target elevated: 26% current → 35% Q4 FY27 → 50–60% over 2–3 years; prior explicit target not stated; mix shift expected to improve margins
The bull-bear ledger
Polyester films segment delivering strong EBIT recovery (₹34.5 Cr) with 8.3% margin and 39.6% revenue growth on pricing power
Elite JV is transformational long-term: Nike anchor pre-commits capacity; ₹1,200–1,400 Cr capex targets 40–45% EBITDA margin on 45,000 MT chips; 2028 ops timeline
VAS mix expansion (26% → 35% → 50–60% in 2–3 years) should provide margin resilience and reduce commodity exposure
Specialty Polymers crater: 49% Q2 decline, 41% H1 decline. Breaks FY27 guidance; caused by customer process change at marquee product.
Razor-thin net margin (1.8%) despite OPM 9.0%; PAT recovery from loss base masks underlying margin pressure
QoQ PAT collapsed 57.9% (Q1 ₹11.6 Cr → Q2 ₹7.8 Cr); specialty EBIT fell 33% Q1→Q2; signals H2 headwinds and cyclical softness
Working capital cycle not normalizing: receivables +₹79 Cr, inventory +₹36 Cr in H1; net debt rose to ₹748.8 Cr despite ₹53.5 Cr repayment
Film margins exposed to crude/MEG cyclicity (current 27–28 rupee spread); if crude normalizes, spread compression risk resumes
Risks, ranked by holder impact
Specialty Polymers demand erosion may be structural, not cyclical
HIGHLargest customer switched chemistry/process; if industry-wide, recovery may not materialize at promised 25% CAGR. Product concentration (50–55% of volume in 2 marquee products) amplifies risk. New product ramp is 6–8 quarters out; near-term tray remains pressured.
Working capital cycle not normalizing despite profit recovery
HIGHReceivables +₹79 Cr, inventory +₹36 Cr in H1; net WC increase ₹86.7 Cr is offsetting debt reduction (₹53.5 Cr repaid but gross debt rose ₹19.8 Cr). If crude/freight inflation persists, this will block the ₹100 Cr FY27 debt target and impair cash conversion.
Elite JV land acquisition timeline: 'very tricky' per management, Q4 FY27 completion uncertain
MEDIUMDescribed as 'very tricky' in Gujarat government-controlled park. Multiple engagement layers cited but no guarantee. If slips into FY28, project commencement (Q4 2028 ops) shifts right, delaying earnings accretion. Execution risk is real.
Film margin cyclicity returns post 8–10 quarters of overcapacity advantage
MEDIUMCurrent 27–28 rupee spread is vulnerable to crude normalization. Industry overcapacity window ends in 8–10 quarters per management; after that, capacity additions and commodity pressure resume. Film EBIT margin 8.3% is healthy now but structurally cyclical.
Loop Industries financial instability may delay Elite funding
MEDIUMLoop is dependent on private equity commitments subject to milestones. If Loop equity rounds delay or fail, Ester's 50% JV equity (₹25 Cr invested so far) may be tied up longer and project timeline slips.
Debt/leverage: gross debt ₹750 Cr, net debt ₹480 Cr above 2–2.25x EBITDA target
MEDIUMManagement acknowledged 'marginally higher than prudent'; refinancing risk is low at current spreads but leverage limits financial flexibility. If specialty decline persists, EBITDA multiple compresses and ratio deteriorates.
How the street is positioned
The post-result price action tells the story the analysts are reading. The stock popped 1.61% on day 1 from ₹87.56 (pre-result) and held momentum, reaching ₹93 by day 5 (a 6.21% total move). That pop is muted for a quarter that delivered ₹7.8 Cr profit on a ₹15.8 Cr loss year-ago (150% swing). The street, correctly, is seeing through the accounting optics to the underlying issues: specialty guidance miss of 40+ percentage points, working capital eating debt progress, and a razor-thin 1.8% net margin that signals no durable margin expansion. The post-result hold (day 5 move sustained) suggests the market has priced in a baseline recovery case but is not excited about it.
Valuation and drawdown context: Ester sits at ₹93, down 51% from its all-time high of ₹190 but up 35.67% off the 52-week low of ₹68.55. The stock trades above its 20-day SMA (₹90.14), 50-day SMA (₹90.69), and 200-day SMA (₹92.42), signaling a near-term uptrend bias. RSI of 54.5 is neutral — neither overbought nor oversold. Volume trend is normal. The drawdown from ATH remains substantial; whether this represents opportunity or a warning depends on the debate below.
Institutional positioning is notably thin. FII holdings are negligible (0.03% as of Q1 FY-27), DII holdings are 0.16%, and promoters own 62.32%. This is a promoter-locked company with minimal institutional money. No bulk or block activity is noted near the highs, suggesting no promoter trim or insider selling. The absence of FII/DII suggests the story is not attracting foreign or domestic institutional money — yet another signal that the street views this as a recovery case, not an accretion case.
The debate
What to watch next (the concrete questions that resolve the debate)
1 · Specialty Polymers bottoming and new product approvals
Q3 H2 FY27 will show whether specialty stabilizes or continues free-fall. Management expects 'recovery from H2 onwards' as new products mature into commercial approvals. Track: (a) volume stabilization in core products, (b) new product revenue contribution (6–8 products in 6–8 quarter ramp), (c) customer count expansion (now 15–16 from 6–7). If H2 specialty revenue falls further, the 25% CAGR thesis breaks.
2 · VAS mix acceleration and film margin resilience
Polyester films VAS products are targeting 26% → 35% (Q4 FY27) → 50–60% (2–3 years). Watch: (a) does VAS reach 35% by Q4 (only 2 quarters away; current pace ~25% YoY growth), (b) what margin uplift does the mix shift deliver (management claims 200–300 bps headroom from VAS spread premium), (c) does film EBIT margin hold above 8% if crude normalizes? This will show whether the model can sustain profitability without commodity tailwinds.
3 · Working capital normalization and debt trajectory
H1 FY27 showed ₹86.7 Cr WC increase; if H2 brings normalization (flat WC), Ester can deliver closer to the ₹100 Cr full-year debt repayment target. Track: (a) receivables cycle (normalize to prior years' days sales outstanding), (b) inventory days (crude/freight cost inflation subsiding), (c) net debt trend. If WC remains elevated into Q4, the 2–2.25x EBITDA target slips further and refinancing risk rises.
4 · Elite JV land acquisition and project commencement
Management target Q4 FY27 (Oct–Dec 2026) for land acquisition completion in Gujarat; commercial ops targeted Q4 2028. Watch: (a) land position by year-end, (b) project financing tie-ups (PE commitments from Loop's side), (c) any capex or timeline adjustment. If land acquisition slips to FY28, the entire Q4 2028 ops timeline shifts right, delaying earnings accretion to 2029.
The number to track from here
Forget reported PAT (it's recovering from a loss, optics don't matter). Track H2 FY27 specialty polymers volume and new product revenue contribution. If specialty stalls or continues falling, the entire thesis — that new products will drive 25% CAGR recovery from the FY27 base — breaks. That's the single question that matters. If specialty stabilizes and new products start contributing, then Elite optionality and VAS mix upgrade become relevant. Until then, Ester is a hold-and-watch: films are real, but specialty is the make-or-break. And be honest about timelines: it's a 2–3 quarter wait to see if the specialty thesis holds or cracks further. The post-result pop didn't hold the headline momentum because the street, correctly, was unconvinced.
Ester's Q2 FY-27 is a study in optics masking substance. Headline PAT swung 150%, but the company broke guidance on its second-biggest segment, watched debt grow despite repayment efforts, and delivered a margin so thin (1.8% net) that the profit recovery looks more like a low base rebound than durable expansion. Polyester films are the strength; Elite JV is the optionality; specialty polymers is the crisis. The stock's muted post-result pop is the market's judgment — a recovery that stumbled before it started.
This is not a hold for conviction. It's a hold for the next 2–3 quarters to see if specialty polymeric products bottom and new product approvals materialize. If they do, Ester re-rates. If they don't, the stock has much further to fall from a 51% drawdown that was already steep. Watch specialty volume, not reported profit. That's where the debate resolves.
Recovery clouded by specialty polymer crisis
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B-
Hit consolidated H1 revenue/profit recovery trajectory, but missed specialty polymers FY27 guidance. Working capital surge (₹86.7 Cr) not called in prior guidance. Now more candid on challenges.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 shows polyester film recovery (EBIT ₹34.5 Cr, margin 8.3%) and consolidated revenue growth of 25.3%, but undermined by specialty polymers demand crater (-49% revenue, -41% H1), which breaks FY27 guidance (supposed flat-to-single-digit, not -40%). Elite project is transformational long-term (45,000 MT, Nike anchor, 40-45% EBITDA) but 2028 execution risk. Near-term catalysts: new specialty products ramp and crude/freight stabilization to ease working capital pressure.
₹443.8 Cr
Revenue · +25.3% YoY₹7.8 Cr
Reported PAT · +149.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
EBIT turnaround in polyester films: INR 34.5 Cr vs loss INR 6.2 Cr YoY
METConsolidated OPM 9.0%, PAT INR 7.8 Cr vs loss INR 15.8 Cr, segment EBIT recovery evident
Specialty Polymers segment declined 49% to INR 29.3 Cr from INR 57.4 Cr in Q2
METSpecialty Polymers H1 INR 62 Cr (down 41% YoY), severe demand erosion acknowledged
VAS products grew ~25% in polyester films, targeting 35% by Q4 FY27
UnverifiedManagement reiterated 35% target Q4, 50-60% over 2-3 years; no prior explicit quarterly target
rPET to exceed 100% capacity by exit quarter; installed 28,000 MT
MISSNo utilization data; Q2 volume 1,437 MT annualizes ~5,700-6,000 MT = ~20% utilization
Debt repayment on track: ₹53.5 Cr in H1 toward ₹100 Cr target
OVERSTATEDDebt rose from ₹729 Cr to ₹748.8 Cr due to WC buildup despite repayment; net debt pressure
Earnings quality
What changed since the last call
Specialty Polymers FY27 guidance reset
DowngradeAcknowledged 49% Q2 decline (INR 29.3 Cr from INR 57.4 Cr), -41% H1 (INR 62 Cr from INR 105 Cr). Prior target flat-to-single-digit clearly missed. Now guiding 25% CAGR from FY27 depressed base.
Working capital headwind unveiled
DowngradeReceivables increased ₹79 Cr, inventory ₹36 Cr in H1 due to crude/freight inflation not called out prior. Net WC burden ₹86.7 Cr limiting debt reduction to ₹53.5 Cr (vs ₹100 Cr target needs acceleration).
rPET capacity utilization unverified
WithdrawnPrior claim 'rPET to exceed 100% capacity by exit quarter' not substantiated. 28,000 MT installed, Q2 volume 1,437 MT implies ~20% utilization. Guidance unclear or unmet.
Elite JV scope confirmed
New45,000 MT polyester chips, ₹1,200-1,400 Cr capex, 40-45% EBITDA margin, Nike anchor customer, leading sports brand LOI for 15,000 MT/year. New quantified transformational play, 2028 timeline.
Specialty films VAS target elevated
UpgradePolyester films VAS share at 26% in Q2, targeting 35% by Q4 FY27, then 50-60% over 2-3 years (prior target not explicit). Mix margin uplift expected to improve film profitability.
The Q&A
Analysts pressed hard on specialty polymer collapse (3 separate question threads), debt/WC stress (3), Elite project execution (2), and margin sustainability (3). Management candidly acknowledged specialty demand erosion (process change at largest customer, technology shift), WC pressure, and execution risks (land acquisition in Gujarat 'very tricky'). Defensive on timelines (new products pending customer approvals, 6-8 quarter ramp). No major evasions, moderate Q&A transparency.
Film cyclicity sustainability — Vishal Bhalada, Valerium Advisors
PartialDemand growing 8-10% YoY; capacity addition lagging; next 8-10 quarters overcapacity should resolve. Specialty films becoming 50-60% of portfolio will provide margin resilience and reduce commodity exposure.
Specialty polymer recovery mechanics — Vishal Bhalada, Valerium Advisors
PartialBiggest challenge is customer approvals and deployment delays. Products at different approval stages with 27 customers. Target 50-60% specialty share will bring EBITDA margin to sustainable 15% profile. Specific margin per product not quantified.
Elite project valuation and consolidation — Vishal Bhalada, Valerium Advisors
Answered45,000 MT chips, ₹1,200-1,400 Cr capex, 40-45% EBITDA margins. 50-50 JV; only bottom-line (PAT) consolidated, not top-line. ₹50 Cr total equity invested (₹25 Cr each from Ester and Loop). No debt required for Elite. Pre-sold ~50% volume to Nike and leading sports brand.
Loop Industries financial risk — Ravi Nandha, individual investor
AnsweredElite requires only equity, no debt from Loop. Loop has commitments from private equity firms subject to milestones (land acquisition, debt tie-up). Ester confident in Loop's PE backing and project progression. No plan B needed.
Specialty polymer product concentration — Ravi Nandha, individual investor
PartialTwo marquee products contribute 50-55% of volume; other products at 40-45% growth quarterly. Expanded customer base from 6-7 to 15-16 customers. 27 customers in different approval stages across 7-8 products. Not concentrated long-term.
Elite land acquisition risk — Surendar, individual investor (Hindi)
PartialLand acquisition is 'very tricky' in Gujarat (government-controlled park). Multiple levels of engagement with government. Expect completion by Q4 FY27 (Oct-Dec). First right will be Hyderabad, second location TBD.
Specialty polymer customer loss root cause — Amit Kumar, Determined Investments
AnsweredCustomer undergone technology/process change and switched to different chemistry. Market lost at that customer; others still using. Loss of market at largest customer in that product. Pipeline of new products mitigates risk going forward.
EBITDA margin compression Q1→Q2 — Deepak, Cap Grow Capital
AnsweredSpecialty polymers demand decline is primary driver. EBITDA margin expansion 250 bps YoY due to higher realization in films. Margin pressure from antidumping duty on China imports helping local producers. Specialty film sales volume up 26% YoY.
PET chip/film spread and crude outlook — Deepak, Cap Grow Capital
AnsweredCurrent spread 27-28 rupees; expected to remain stable. Crude down to 75-80 levels taking effect. May see spread drop as crude prices adjust. International pricing indices followed; Reliance-declared prices not moving much despite pressure.
Value-added product margin expansion — Deepak, Cap Grow Capital
PartialSpecialty film spreads highly customized by customer (50-152 rupees range). No standard pricing model. Different products, different customers = varied margins. As VAS share grows, overall film margins will improve.
Elite project debt implications — Deepak, Cap Grow Capital
AnsweredGross debt ₹750 Cr (interest-bearing), term debt ₹480 Cr, WC debt ₹270 Cr. Net debt to EBITDA target 2-2.25x. Ester invested ₹25 Cr in Elite (50% JV with Loop at ₹50 Cr total). Debt repayment ₹53.5 Cr in H1, on track for ₹100 Cr full-year.
Debt reduction and cyclicity trap — Saket Kapoor, Kapoor & Company
PartialSpecialty polymer business has structural tailwinds (NDA/government support for recycled content, global sustainability mandates). 80-90% of company efforts focused on specialization. 25% CAGR confidence backed by robust pipeline and customer approvals. Debt trajectory good despite cyclicity.
Industry profile debt levels — Saket Kapoor, Kapoor & Company
Partial2-2.25x is slightly higher than prudent target but reasonable for growth/investment phase. Currently marginally above prudent level; working hard to bring down. Target sustainable as WC normalizes and specialty products ramp.
Elite JV consolidation and earnings accretion — Saket Kapoor, Kapoor & Company
AnsweredBottom-line (PAT) only consolidated, not top-line. Significant capex (₹1,200-1,400 Cr) but mostly funded by Loop and project financing. Once operational (2028), 50% share of 40-45% EBITDA margin facility will be meaningful to bottom-line.
Specialty polymer H2 FY27 outlook — Saket Kapoor, Kapoor & Company
PartialDifficult to reach that level in H2 this year. But from FY27 as base, expect 25% YoY growth. New products in advanced approval stages likely to mature in next quarter, driving recovery from H2 onwards.
Guidance
Specialty Polymers 25% CAGR over 3-5 years from FY27 base
MediumFY27 reset year; new products in 6-8 quarter ramp with 27 customer projects in approval. Prior 20% CAGR guidance implicitly abandoned after -41% H1 decline.
Polyester Films VAS share 35% by Q4 FY27, 50-60% over 2-3 years
HighCurrently 26% of volume. Mix shift will support margin expansion. Pricing power demonstrated (39.6% revenue growth on 13.9% volume)
Elite JV revenue 45,000 MT polyester chips at 40-45% EBITDA margin
MediumCommercial ops Q4 2028. Nike + leading brand customer pre-committed to ~50% capacity. Execution risks (land, funding) present but mitigation plans cited.
Specialty Polymers target 15% EBITDA margin sustainable long-term
LowCurrently 33.9% (Q2) but from much smaller revenue base. Margin held despite 49% revenue decline, suggesting pricing power. Long-term feasibility dependent on new product mix maturation.
Film segment 8.3% EBIT margin in Q2; medium-term 10-15% target
MediumVAS mix expansion from 26% to 35-50% expected to lift margins 200-300 bps. Crude/freight volatility poses near-term risk.
Elite JV 40-45% EBITDA margin on 45,000 MT chips
MediumRecycled content commands premium pricing. Nike/brand commitments suggest customer willingness to pay. Execution risk on cost structure.
Elite project ₹1,200-1,400 Cr capex over 2026-2028
HighDetailed project economics disclosed. Majority funded by Loop Industries PE backing and project financing. Ester equity ₹25 Cr already invested.
Routine capex INR 15.1 Cr in H1 FY27; no major expansion planned
HighCapex expected to remain moderate apart from Elite. Specialty polymer new product development capex contained within normal budget.
Risks the call surfaced
Specialty Polymers demand erosion
HighLargest marquee specialty product lost market at primary customer due to customer's technology/process change. Q2 revenue down 49%, H1 down 41%. Management acknowledged this as demand erosion, not pricing issue.
Working capital pressure
HighReceivables increased ₹79 Cr, inventory ₹36 Cr in H1 due to crude/freight cost inflation and longer transit times. Net WC increase ₹86.7 Cr is offsetting debt repayment efforts.
Elite project execution risk
MediumElite JV targets land acquisition by Q4 FY27 and commercial ops Q4 2028. Land acquisition in Gujarat described as 'very tricky' by management. Funding dependent on Loop Industries PE commitments.
Cyclical film margin volatility
MediumPolyester film spread currently 27-28 rupees, exposed to crude oil volatility. Film EBIT margin 8.3% in Q2; multiple analysts flagged cyclicity risk. Industry capacity additions lagging demand (next 8-10 quarters should be favorable), but after that risk rises.
Debt and leverage stress
MediumGross debt ₹750 Cr (interest-bearing), net debt ₹480 Cr. Net debt to EBITDA currently above 2.25x target. Debt repayment ₹53.5 Cr in H1 on track, but WC surge limiting full progress. Management acknowledged 'marginally higher than prudent level.'
Management
Score 6/10. Candid on challenges (specialty demand erosion, WC stress, land acquisition 'very tricky'). Transparent on debt position and working towards 2-2.25x target. Some hedging on timelines (new products pending approvals, 6-8 quarter ramp). Mixed. Polyester Films delivered recovery (EBIT ₹34.5 Cr, margin 8.3%); rPET capacity installed but utilization low (~20%); Specialty Polymers guidance missed (flat-to-single-digit FY27 → -41% H1). Debt repayment on track (₹53.5 Cr of ₹100 Cr target).
1 · Q3-Q4 FY27
New specialty polymer products ramp (6-8 products in 6-8 quarter pipeline, 27 customer projects)
2 · Q4 FY27
Specialty films VAS target 35% of mix; polyester film margin expansion if crude stabilizes
3 · Q4 FY27
Elite project land acquisition completion in Gujarat (described as 'very tricky', execution uncertainty)
Near-term catalysts: new specialty products ramp and crude/freight stabilization to ease working capital pressure.
Ester swings to ₹7.84 Cr consolidated PAT YoY; polyester film offsets 49% polymer slump
revenue +25.29% · margins expanding
₹443.76 Cr
+25.29% YoY
₹7.84 Cr
1.75%
+6.2pp YoY
₹0.75
Ester Industries' consolidated PAT turned positive at ₹7.84 Cr in Q2 FY27, reversing a ₹15.78 Cr loss in Q2 FY26, as consolidated revenue grew 25.3% YoY to ₹443.76 Cr from ₹354.19 Cr. Standalone PAT was ₹6.09 Cr on revenue of ₹360.11 Cr — not materially different from the consolidated story. No Street consensus for this specific quarter turned up in public previews (none was found for Q2 FY27 despite similar previews existing for Q1 FY27), so the print cannot be benchmarked against analyst estimates; management has also not issued a separate press release with this filing to cross-check tone.
Q2 FY-2027 vs prior quarters
The turnaround was driven entirely by the polyester chips-and-film segment, which swung from a ₹6.13 Cr segment loss a year ago to a ₹34.50 Cr profit this quarter on 39.7% YoY revenue growth (₹414.49 Cr vs ₹296.82 Cr) — more than offsetting a 49% YoY collapse in specialty polymers revenue (₹29.27 Cr vs ₹57.37 Cr) and a 53.3% drop in that segment's profit (₹9.93 Cr vs ₹21.24 Cr). Consolidated operating margin expanded YoY to roughly 10.0% from 4.03%, and net margin to 1.77% from -4.42%, but both compressed sequentially: PAT fell 57.9% QoQ to ₹7.84 Cr from ₹18.62 Cr in Q1 FY27 even as revenue rose only 2.7% QoQ, and OPM slipped from 11.37% in Q1. EPS was ₹0.75 against ₹1.84 in Q1 FY27.
The stock went into the print at ₹89.14, down 6.7% over the past month of trading.
For context: revenue is at a 6-quarter high.
₹2,000-2,200 Cr revenue target via existing capacity in 2–3 years; Specialty Polymers: 20% CAGR over 3–5 years (flat-to-single-digit FY27); ₹100 Cr debt repayment this year; rPET to exceed 100% rated capacity by exit quarter.
— This quarter: missed
Against prior management guidance from the Q1 FY27 concall, this quarter is mixed-to-missed: specialty polymers was flagged for 'flat-to-single-digit' FY27 growth, but the segment fell 49% YoY this quarter — a clear miss on that specific marker, even as the broader ₹2,000-2,200 Cr revenue target (via existing capacity, over 2-3 years) is too early to grade on a single quarter. On the ₹100 Cr debt-repayment target for the year, consolidated total borrowings (current + non-current) rose to ₹748.76 Cr as of 30 September 2026 from ₹728.90 Cr at FY26-end — a ₹19.9 Cr increase over H1, running counter to that guidance so far. The filing gives no update on the rPET capacity-utilization target ('exceed 100% of rated capacity by exit quarter'). The quarter's other governance event was the 40th AGM on 24 September 2026, with a ₹0.25 dividend proposed, unrelated to the operating print.
W1
Specialty polymers: management guided flat-to-single-digit FY27 growth; segment revenue fell 49% YoY this quarter — watch Q3 for stabilization
W2
Net debt: consolidated borrowings rose ~₹19.9 Cr in H1 FY27 against a stated ₹100 Cr full-year repayment target — confirm reversal in H2
W3
rPET capacity utilization vs. management's 'exceed 100% of rated capacity by exit quarter' target — not disclosed this quarter, needs confirmation
Converted from ₹ Lakhs to ₹ Crore. Consolidated PBT ₹9.87 Cr is after deducting ₹0.70 Cr share of JV (Ester Loop Infinite Technologies) loss from segment PBIT of ₹10.58 Cr. No exceptional/one-off items disclosed in either statement. The comparison-context year-ago EPS (₹1.62) looks inconsistent with the reported ₹15.78 Cr loss that quarter and was not used in the narrative.